New trials, publications, preprints and grants on this target, month by month.
Publication
Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53, STAG2, and CDKN2A Alterations.
4 Nov 2026· Journal of clinical oncology : official journal of the American Society of Clinical Oncology· PUBMED
Publication
Expression of CDKN2A Gene for Early Detection of Head and Neck Squamous Cell Carcinoma - An Evaluative Study.
28 Oct 2026· Indian journal of dental research : official publication of Indian Society for Dental Research· PUBMED
Publication
EGFRvIII overexpression and loss of mouse-specific CDKN2A in glial cells leads to spontaneous gliomagenesis in a novel mouse model.
24 Oct 2026· Neuro-oncology· PUBMED
Publication
Association of CDKN2A overexpression with poor prognosis, radioresistance, and immunosuppression in colorectal cancer.
16 Oct 2026· Frontiers in cell and developmental biology· PUBMED
Publication
CDKN2A deletion associated with poor prognosis in patients with TERT promoter wild-type, IDH wild-type glioblastoma.
10 Oct 2026· Brain tumor pathology· PUBMED
Publication
Pediatric and Adult Sinonasal Phosphaturic Mesenchymal Tumors: CDKN2A Copy Number Alterations and Their Association with Recurrence.
6 Oct 2026· Head and neck pathology· PUBMED
Publication
CDKN2A alterations in solid tumors: From biological mechanisms to clinical applications, with special emphasis on central nervous system tumors.
22 Sept 2026· Histology and histopathology· PUBMED
Publication
Assessing melanoma and pancreatic cancer risks in diverse CDKN2A heterozygote populations.
22 Sept 2026· Genetics in medicine : official journal of the American College of Medical Genetics· PUBMED
Publication
Low frequency of MTAP co-deletion with CDKN2A in peritoneal mesothelioma suggests an independent diagnostic role for MTAP.
21 Sept 2026· Histopathology· PUBMED
Publication
Exploring the Melanoma and Pancreatic Cancer Phenotype of a Potential CDKN2A Founder Variant, I49T (c.146T>C; p.Ile49Thr), in Individuals of Predominantly Mexican Ancestry.
17 Sept 2026· JCO precision oncology· PUBMED
Publication
CDKN2A c.146T>C (I49T) in Mexican-ancestry individuals: Findings from melanoma and population cohorts.
15 Sept 2026· JAAD international· PUBMED
Publication
Age-specific pancreatic cancer risk in Italian CDKN2A families.
14 Sept 2026· Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver· PUBMED
Publication
A Pathway to Chordoma Treatment: A Review on CDKN2A and Therapeutic Targeting.
19 Aug 2026· Cancers· PUBMED
Trial
A Comparative Usability Study of Two Total Body Skin Imaging Systems
3 Aug 2026· NA · NOT_YET_RECRUITING· CTGOV
Trial
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
27 Jul 2026· PHASE2 · RECRUITING· CTGOV
Publication
The genomic landscape and treatment outcomes associated with CDKN2A/MTAP loss in patients with non-small cell lung cancer.
27 Jul 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
15 Jul 2026· JCO precision oncology· PUBMED
Publication
Immunohistochemical Loss of MTAP as a Diagnostic and Prognostic Surrogate of CDKN2A/B Homozygous Deletion: A Narrative Review.
1 Jul 2026· Diagnostics (Basel, Switzerland)· PUBMED
Publication
The Role of STAG2, CDKN2A, and TP53 Genes in Ewing Sarcoma: A Report of a Rare Case of Primary Ewing Sarcoma of the Kidney With Favorable Outcome.
29 Jun 2026· Journal of pediatric hematology/oncology· PUBMED
Publication
A Greek Case-Control Replication Study of IKZF1 rs4132601 and CDKN2A rs3731217 in Childhood Acute Lymphoblastic Leukemia.
10 Jun 2026· Genes· PUBMED
Publication
Lower artificial intelligence and clinician-derived dermoscopy scores in melanomas from CDKN2A pathogenic variant carriers compared to sporadic cases.
6 Jun 2026· Journal of the American Academy of Dermatology· PUBMED
Preprint
Disruption of CTCF binding by germline non-coding variants in CDKN2B suppress CDKN2A expression and predispose to melanoma.
2 Jun 2026· medRxiv : the preprint server for health sciences· PUBMED
Publication
Association of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas.
1 Jun 2026· Journal of neuropathology and experimental neurology· PUBMED
Publication
TP53, HIF1A, and CDKN2A in Hepatocellular Carcinoma: Roles in Senescence, Ferroptosis, and Prognosis.
1 Jun 2026· Clinical and translational gastroenterology· PUBMED
Publication
CDKN2A alterations as possible molecular link between environmental pollutants and pathogenesis of liver cancer: Epidemiology, mechanisms, and insights.
27 May 2026· Hepatobiliary & pancreatic diseases international : HBPD INT· PUBMED
Publication
Clinicogenomic Landscape of MTAP-Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent CDKN2A Alterations and Driver Mutations.
22 May 2026· JCO precision oncology· PUBMED
Preprint
Large distant deletion disrupts CDKN2A enhancer and predisposes to melanoma.
18 May 2026· medRxiv : the preprint server for health sciences· PUBMED
Publication
Association between breast cancer, pancreatic cancer, and melanoma in a CDKN2A variant common in the Hispanic population.
13 May 2026· Familial cancer· PUBMED
Publication
MTAP loss in gastrointestinal cancers is associated with CDKN2A deletion, poor prognosis in gastric carcinoma, and potential relevance for PRMT5-targeted therapy.
13 May 2026· Scientific reports· PUBMED
Publication
Possible Founder Effect of the CDKN2A c.146T>C Variant in the Mexican Population: Phenotypic Characterization.
30 Apr 2026· Genes· PUBMED